Kuno van der Post Ph.D
OmniComm Systems, Inc.
Fort Lauderdale, FL, Oct 9, 2012 – OmniComm Systems, Inc., one of the fastest growing companies in the Electronic Data Capture marketplace, today announced that its TrialMaster® Study Data Tabulation Model (SDTM) Export Utility won the Bronze medal at the 2012 Society for Clinical Data Management’s (SCDM) 2012 Data Driven Innovation Award Ceremony. Created in 2007, the Data Driven Innovation Award Ceremony is held once a year at the Society for Clinical Data Management’s Annual Meeting to recognize important innovations within the industry that impact the quality and efficiency of clinical data management efforts among clinical trial research.
OmniComm’s SDTM Export Utility was selected by a panel of industry experts among a highly competitive field of 16 entrants and 5 finalists including Clinical Ink, Quintiles, PHT and Medidata. OmniComm’s TrialMaster Export Utility was specifically designed to automate and facilitate the generation of SDTM datasets for clinical trial analysis and FDA submission. The SDTM format has gained significant traction in the industry and is the FDA’s preferred format for submission of clinical trial data.
“This award underscores the value of innovative technology in solving complex problems within clinical research,” said Stephen Johnson, President & COO of OmniComm. “In the past, most companies dealt with the generation of SDTM datasets as a separate programming exercise at the end of the study, causing needless delays and inefficiency. OmniComm’s Export Utility leverages the TrialMaster study designer to automatically map the source data to the SDTM format, significantly reducing the time to submission.”
OmniComm’s award winning technology for generating SDTM and other custom export formats has been deployed in several dozen clinical trials over the past year and has resulted in a significant reduction of time and resources in preparing for FDA submission.
OmniComm Systems, Inc. (www.OmniComm.com) provides customer-driven Internet solutions to pharmaceutical, biotechnology, and medical device organizations that conduct life changing clinical trial research. OmniComm's growing base of satisfied customers is a direct result of the company's commitment to deliver products and services that ensure ease of use, faster study build, ease of integration and better performance. OmniComm Systems, Inc. has U.S. headquarters in Fort Lauderdale, FL and European headquarters in Bonn, Germany, with satellite offices in New Jersey and the United Kingdom, as well as sales offices throughout the U.S. and Europe.
Safe Harbor Disclaimer
Statements made by OmniComm included in this release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve a number of risks and uncertainties such as the Company's ability to obtain new contracts and accurately estimate net revenues due to uncertain regulatory guidance, variability in size, scope and duration of projects, and internal issues at the sponsoring client, integration of acquisitions, competitive factors, technological development, and market demand. As a result, actual results may differ materially from any financial outlooks stated herein. Further information on potential factors that could affect the Company's financial results can be found in the Company's Reports on Form 10-K and 10-Q filed with the Securities and Exchange Commission. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.